CVS Stock Analysis: CVS Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 119.776m USD | 12M Return: 34.6% | US1266501006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 771M
EPS Trend: -38.4%
Qual. Beats: 2
Rev. Trend: 99.4%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CVS Health Corporation is a U.S. healthcare company operating through three segments: Health Care Benefits (insurance products including medical, dental, behavioral health, Medicare Advantage, Medicare Supplement, and Medicaid plans), Health Services (pharmacy benefit management, or PBM, solutions such as plan design, formulary management, specialty and mail-order pharmacy, and clinical services), and Pharmacy & Consumer Wellness (retail sale of prescription and over-the-counter drugs, consumer health products, and related pharmacy services to care facilities). The company serves a broad customer base spanning employer groups, individuals, health plans, government programs, labor unions, and expatriates.
Founded in 1963 and headquartered in Woonsocket, Rhode Island, the company was originally known as CVS Caremark Corporation before adopting its current name in September 2014. It trades on the NYSE under the ticker CVS and is classified within the Health Care sector as a large-cap Health Care Services company.
CVS operates a vertically integrated healthcare model, combining a major PBM (Caremark) with a large retail pharmacy footprint and a health insurance carrier, an uncommon structure in the U.S. healthcare industry that allows it to coordinate benefits, drug pricing, and point-of-care delivery within a single company.
- Aetna Medicare Advantage margins hinge on star ratings and MA reimbursement rates
- GLP-1 drug spending boosts pharmacy revenue while pressuring medical loss ratios
- PBM rebate model faces escalating federal and state regulatory scrutiny
| Net Income: 4.91b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.78 > 1.0 |
| NWC/Revenue: -2.82% < 20% (prev -4.79%; Δ 1.97% < -1%) |
| CFO/TA 0.06 > 3% & CFO 14.8b > Net Income 4.91b |
| Net Debt (77.2b) to EBITDA (13.4b): 5.76 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.28b) vs 12m ago 1.02% < -2% |
| Gross Margin: 14.15% > 18% (prev 13.82%; Δ 0.33% > 0.5%) |
| Asset Turnover: 162.1% > 50% (prev 149.7%; Δ 12.45% > 0%) |
| Interest Coverage Ratio: 2.87 > 6 (EBIT TTM 8.89b / Interest Expense TTM 3.10b) |
| A: -0.05 (Total Current Assets 75.3b - Total Current Liabilities 87.0b) / Total Assets 254b |
| B: 0.26 (Retained Earnings 65.4b / Total Assets 254b) |
| C: 0.03 (EBIT TTM 8.89b / Avg Total Assets 256b) |
| D: 0.46 (Book Value of Equity 79.7b / Total Liabilities 174b) |
| Altman-Z'' = 1.25 = BB |
| DSRI: 0.92 (Receivables 40.3b/40.7b, Revenue 415b/387b) |
| GMI: 0.98 (GM 13.82% / 14.15%) |
| AQI: 0.99 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.07 (Revenue 415b / 387b) |
| TATA: -0.04 (NI 4.91b - CFO 14.8b) / TA 254b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at USD 92.90 with a total of 4,100,958 shares traded. Over the past week, the price has changed by -2.12%, over one month by -13.23%, over three months by +3.03% and over the past year by +34.60%.
Current recommended Stop Loss: 89.70 (which is 3.4% or 1.3 ATR below the current price).
CVS Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CVS.
- StrongBuy: 18
- Buy: 6
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 116.1 | 25% |
P/E Trailing = 24.7098
P/E Forward = 12.7065
P/S = 0.2903
P/B = 1.5028
P/EG = 0.2516
Revenue TTM = 415b USD
EBIT TTM = 8.89b USD
EBITDA TTM = 13.4b USD
Long Term Debt = 59.5b USD (from longTermDebt, last quarter)
Short Term Debt = 3.87b USD (from shortTermDebt, last quarter)
Debt = 91.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 14.9b
Net Debt = 77.2b USD (calculated: Debt 91.2b - CCE 14.0b)
Enterprise Value = 197b USD (120b + Debt 91.2b - CCE 14.0b)
Interest Coverage Ratio = 2.87 (Ebit TTM 8.89b / Interest Expense TTM 3.10b)
EV/FCF = 16.76x (Enterprise Value 197b / FCF TTM 11.8b)
FCF Yield = 5.97% (FCF TTM 11.8b / Enterprise Value 197b)
FCF Margin = 2.83% (FCF TTM 11.8b / Revenue TTM 415b)
Net Margin = 1.18% (Net Income TTM 4.91b / Revenue TTM 415b)
Gross Margin = 14.15% ((Revenue TTM 415b - Cost of Revenue TTM 356b) / Revenue TTM)
Gross Margin QoQ = 14.84% (prev 15.56%)
Tobins Q-Ratio = 0.78 (Enterprise Value 197b / Total Assets 254b)
Interest Expense / Debt = 3.40% (Interest Expense 3.10b / Debt 91.2b)
Taxrate = 15.83% (916.0m / 5.79b)
NOPAT = 7.48b (EBIT 8.89b * (1 - 15.83%))
Current Ratio = 0.87 (Total Current Assets 75.3b / Total Current Liabilities 87.0b)
Debt / Equity = 1.14 (Debt 91.2b / totalStockholderEquity, last quarter 79.7b)
Debt / EBITDA = 5.76 (Net Debt 77.2b / EBITDA 13.4b)
Debt / FCF = 6.57 (Net Debt 77.2b / FCF TTM 11.8b)
Total Stockholder Equity = 76.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.92% (Net Income 4.91b / Total Assets 254b)
RoE = 6.43% (Net Income TTM 4.91b / Total Stockholder Equity 76.3b)
RoCE = 6.55% (EBIT 8.89b / Capital Employed (Equity 76.3b + L.T.Debt 59.5b))
RoIC = 4.78% (NOPAT 7.48b / Invested Capital 157b)
WACC = 4.73% (E(120b)/V(211b) * Re(6.15%) + D(91.2b)/V(211b) * Rd(3.40%) * (1-Tc(0.16)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.99 | Cagr: 0.56%
[DCF] Terminal Value 77.97% ; FCFF base≈8.97b ; Y1≈10.3b ; Y5≈15.1b
[DCF] Fair Price = 117.6 (EV 228b - Net Debt 77.2b = Equity 150b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -38.37 | EPS CAGR: -5.80% | SUE: 2.54 | # QB: 2
Revenue Correlation: 99.40 | Revenue CAGR: 6.41% | SUE: 3.16 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.64 | Chg30d=-4.51% | Revisions=-50% | Analysts=22
EPS current Year (2026-12-31): EPS=7.95 | Chg30d=+6.77% | Revisions=+71% | GrowthEPS=+17.8% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=8.51 | Chg30d=+1.13% | Revisions=+59% | GrowthEPS=+7.0% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: +36% (up=27, down=12)